MYC and cancer: In prostate cancer, USP1 was reported to stabilize histone demethylase lysine-specific demethylase 4A (KDM4A) and indirectly activates the expression of C-MYC, which is a driver of deregulated cancer metabolism; inhibition of USP1 by ML323, a nanomolar inhibitor of USP1-UAF1 with remarkable selectivity, caused a dramatic downregulation of C-MYC and sensitized cells to enzalutamide treatment [81, 82].